Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adult ALL/MRD2019 treatment protocol
jRCTs071190036Active, not recruiting
- Sponsor
- ICMR-Regional Medical Research Centre
- Start
- Jan 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of dasatinib and ponatinib in acute lymphoblastic leukemia (ALL) and Acute Lymphoblastic Leukemia BCR-ABL1-Negative (2 arms), sponsored by ICMR-Regional Medical Research Centre. Primary endpoint: 3-year disease-free survival. Started Jan 2020; status: active, not recruiting.
02
Drugs
dasatinibponatinib
03
Conditions
acute lymphoblastic leukemia (ALL)Acute Lymphoblastic Leukemia BCR-ABL1-Negative
Beyond the preview
Go deeper on jRCTs071190036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071190036.